Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials

医学 内科学 安慰剂 科克伦图书馆 糖尿病 不利影响 随机对照试验 餐后 临床试验 2型糖尿病 1型糖尿病 荟萃分析 梅德林 胃肠病学 置信区间 相对风险 胰岛素 内分泌学 替代医学 病理 政治学 法学
作者
Giovanni Musso,Roberto Gambino,Maurizio Cassader,Elena Paschetta
出处
期刊:BMJ [BMJ]
卷期号:: l1328-l1328 被引量:88
标识
DOI:10.1136/bmj.l1328
摘要

Abstract Objective To assess the efficacy and safety of dual sodium glucose cotransporter (SGLT) 1/2 inhibitor sotagliflozin in type 1 diabetes mellitus. Design Meta-analysis of randomised controlled trials. Data sources Medline; Cochrane Library; Embase; international meeting abstracts; international and national clinical trial registries; and websites of US, European, and Japanese regulatory authorities, up to 10 January 2019. Eligibility criteria for selecting studies Randomised controlled trials evaluating the effect of sotagliflozin versus active comparators or placebo on glycaemic and non-glycaemic outcomes and on adverse events in type 1 diabetes in participants older than 18. Three reviewers extracted data for study characteristics, outcomes of interest, and risk of bias and summarised strength of evidence using the grading of recommendations assessment, development, and evaluation approach. Main outcomes were pooled using random effects models. Results Of 739 records identified, six randomised placebo controlled trials (n=3238, duration 4-52 weeks) were included. Sotagliflozin reduced levels of glycated haemoglobin (HbA1c; weighted mean difference −0.34% (95% confidence interval −0.41% to −0.27%), P<0.001); fasting plasma glucose (−16.98 mg/dL, −22.1 to −11.9; 1 mg/dL=0.0555 mmol/L) and two hour-postprandial plasma glucose (−39.2 mg/dL, −50.4 to −28.1); and daily total, basal, and bolus insulin dose (−8.99%, −10.93% to −7.05%; −8.03%, −10.14% to −5.93%; −9.14%, −12.17% to −6.12%; respectively). Sotagliflozin improved time in range (weighted mean difference 9.73%, 6.66% to 12.81%) and other continuous glucose monitoring parameters, and reduced body weight (−3.54%, −3.98% to −3.09%), systolic blood pressure (−3.85 mm Hg, −4.76 to −2.93), and albuminuria (albumin:creatinine ratio −14.57 mg/g, −26.87 to −2.28). Sotagliflozin reduced hypoglycaemia (weighted mean difference −9.09 events per patient year, −13.82 to −4.36) and severe hypoglycaemia (relative risk 0.69, 0.49 to 0.98). However, the drug increased the risk of ketoacidosis (relative risk 3.93, 1.94 to 7.96), genital tract infections (3.12, 2.14 to 4.54), diarrhoea (1.50, 1.08 to 2.10), and volume depletion events (2.19, 1.10 to 4.36). Initial HbA1c and basal insulin dose adjustment were associated with the risk of diabetic ketoacidosis. A sotagliflozin dose of 400 mg/day was associated with a greater improvement in most glycaemic and non-glycaemic outcomes than the 200 mg/day dose, without increasing the risk of adverse events. The quality of evidence was high to moderate for most outcomes, but low for major adverse cardiovascular events and all cause death. The relatively short duration of trials prevented assessment of long term outcomes. Conclusions In type 1 diabetes, sotagliflozin improves glycaemic and non-glycaemic outcomes and reduces hypoglycaemia rate and severe hypoglycaemia. The risk of diabetic ketoacidosis could be minimised by appropriate patient selection and down-titration of the basal insulin dose.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
通通通发布了新的文献求助10
1秒前
liudw完成签到,获得积分10
1秒前
丹丹子完成签到 ,获得积分10
2秒前
时光完成签到,获得积分10
2秒前
3秒前
充电宝应助vsvsgo采纳,获得10
5秒前
123完成签到 ,获得积分10
7秒前
Ammr完成签到 ,获得积分10
7秒前
无限的依波完成签到,获得积分10
7秒前
姽婳wy发布了新的文献求助10
8秒前
lemon完成签到,获得积分10
8秒前
传奇3应助duckspy采纳,获得30
9秒前
陈木木完成签到,获得积分10
10秒前
可可西里完成签到,获得积分10
11秒前
奋斗蜗牛完成签到,获得积分10
11秒前
CipherSage应助眼睛大的擎苍采纳,获得10
11秒前
打打应助小小酥采纳,获得10
12秒前
fox完成签到 ,获得积分10
12秒前
僦是卜够完成签到 ,获得积分10
13秒前
小马甲应助嘉梦采纳,获得10
16秒前
qiqi完成签到,获得积分10
17秒前
17秒前
科研乞丐应助Jerry采纳,获得20
18秒前
vsvsgo发布了新的文献求助10
20秒前
Jeffrey完成签到,获得积分10
21秒前
明理采珊完成签到,获得积分10
21秒前
lll发布了新的文献求助10
21秒前
vsvsgo发布了新的文献求助10
24秒前
慎之完成签到 ,获得积分10
24秒前
我是微风完成签到,获得积分10
24秒前
传奇3应助木子采纳,获得30
26秒前
vsvsgo发布了新的文献求助10
28秒前
feitian201861完成签到,获得积分10
28秒前
30秒前
mmr完成签到 ,获得积分10
31秒前
大知闲闲完成签到,获得积分10
32秒前
陌陌完成签到,获得积分10
32秒前
vsvsgo发布了新的文献求助10
32秒前
科研通AI2S应助sunyanghu369采纳,获得30
34秒前
wlp鹏完成签到,获得积分10
36秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038235
求助须知:如何正确求助?哪些是违规求助? 3575992
关于积分的说明 11374009
捐赠科研通 3305760
什么是DOI,文献DOI怎么找? 1819276
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022